Jenrin Discovery
Ms. Schilberg, Managing Director and CEO of BioAdvance, has more than 20 years’ experience in life sciences. Under her leadership as CEO, BioAdvance has invested $14 million in 25 seed-stage companies and 13 pre-seed projects focusing in areas including Alzheimer’s disease, cancer, diabetes, obesity and infectious diseases. The portfolio companies have gone on to raise more than $900 million in additional funding and six have been sold. Ms. Schilberg’s industry experience includes senior leadership positions at Cephalon, Incara Pharmaceuticals, Advanced Medicine (now Theravance) and Locus Discovery, Inc.
Before joining the industry, Ms Schilberg represented biopharmaceutical companies and universities as a partner with Morgan, Lewis & Bockius. She received a J.D. from the University of Virginia.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Jenrin Discovery
Jenrin Discovery is a privately-held, a company focused on the discovery and development of small-molecule product candidates designed to target peripheral tissues.